GSK4381562 / GSK, Coherus Oncology - LARVOL DELTA

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=141 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Oct 2026 ➔ Sep 2028 | Trial primary completion date: Oct 2026 ➔ Sep 2028

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Colorectal Cancer • Endometrial Cancer • Gastric Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 (clinicaltrials.gov) - P2 | N=360 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Aug 2027 ➔ May 2027 | Trial primary completion date: Sep 2025 ➔ May 2027

Metastases • Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=162 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Dec 2025 ➔ Sep 2026 | Trial primary completion date: Dec 2025 ➔ Sep 2026

Combination therapy • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Endometrial Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=162 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Feb 2027 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Dec 2025

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2023 ➔ Feb 2027 | Trial primary completion date: Feb 2023 ➔ Oct 2024

Combination therapy • Enrollment open • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study (GlobeNewswire) - "Surface Oncology...announced the first patient has been dosed by GlaxoSmithKline (GSK) in the Phase 1 study of GSK4381562 in patients with solid tumors...As a result of this Phase 1 initiation, Surface will receive a $30 million milestone payment and is eligible to receive an additional $700 million in potential future milestone payments, as well as tiered royalties on global net sales."

Trial status • Oncology • Solid Tumor

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=126 | Not yet recruiting | Sponsor: GlaxoSmithKline

Combination therapy • Monotherapy • New P1 trial • Breast Cancer • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021 (GlobeNewswire) - "Surface will receive a $30 million milestone payment in conjunction with the initiation of the first Phase 1 study for GSK4381562 and is eligible to receive an additional $700 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales."

Financing • Oncology

Surface Oncology Announces FDA Clearance of IND Application for GSK4381562, a Novel Antibody Targeting PVRIG (GlobeNewswire) - "Surface Oncology...announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for GSK4381562 (formerly SRF813) to proceed into a first-in-human clinical trial."

IND • Oncology

Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2021 (GlobeNewswire) - "Investigational New Drug (IND) filing for GSK4381562, formerly SRF813, targeting the PVRIG checkpoint and partnered with GlaxoSmithKline, will be filed in Q4 2021.; Data update for SRF617 anticipated at the European Society for Medical Oncology Immuno-Oncology Congress taking place December 8-11, 2021.; Data update for SRF388 anticipated in early 2022."

IND • P1 data • Clear Cell Renal Cell Carcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Hepatocellular Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2021 (GlobeNewswire) - "Selected Anticipated Near-term Corporate Milestones: Investigational New Drug (IND) filing for GSK4381562 formerly, SRF813, targeting the PVRIG checkpoint and partnered with GlaxoSmithKline, anticipated in 2H 2021. Data update from Phase 1 study of SRF617 anticipated in late 2021. Data update from Phase 1 study of SRF388 anticipated in early 2022."

IND • P1 data • Oncology • Solid Tumor

iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations (GlobeNewswire) - “iTeos Therapeutics…and GlaxoSmithKline plc…announced an agreement to co-develop and co-commercialise EOS-448…EOS-448 is currently in an open-label phase I study in patients with advanced solid tumours. GSK and iTeos plan to start combination studies of EOS-448 with dostarlimab in 2022. GSK’608 (anti-CD96 being developed in collaboration with 23andMe) is in phase I as monotherapy and in combination with dostarlimab. GSK expects to submit an Investigational New Drug application for GSK’562 (anti-PVRIG in-licensed as SRF-813 from Surface Oncology) by mid-2022….Under the terms of the collaboration agreement, iTeos will receive an upfront payment of $625 million. iTeos will be eligible to receive up to an additional $1.45 billion in milestone payments, should the EOS-448 programme achieve certain development and commercial milestones.”

IND • Licensing / partnership • New trial • Oncology • Solid Tumor

Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2021 (GlobeNewswire) - “SRF388 clinical data presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, to be held virtually June 4-8, 2021. Webcast to provide data from ongoing SRF388 and SRF617 Phase 1 clinical studies, to be held on Friday, June 4, 2021 at 8:00 a.m. ET. Investigational new drug (IND) filing for SRF813, partnered with GlaxoSmithKline, anticipated in 2021.”

IND • P1 data • Oncology

Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2020 (GlobeNewswire) - “Selected Anticipated Near-term Corporate Milestones: Preclinical data presentations for SRF617 and SRF388 at the American Association for Cancer Research (AACR) Virtual Annual Meeting in April; Targeting the American Society of Clinical Oncology (ASCO) Virtual Annual Meeting in June for detailed clinical data presentations for SRF617 and SRF388; Investigational new drug (IND) filing for SRF813 anticipated in 2021.”

Clinical data • IND • Preclinical • Oncology

Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program (GlobeNewswire) - “Surface Oncology…announced an agreement for GSK to exclusively license worldwide development and commercial rights to Surface Oncology’s preclinical program SRF813, a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells. Under the terms of the agreement, GSK will make an $85 million upfront payment. In addition, Surface Oncology may receive up to an additional $730 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales.”

Licensing / partnership • Oncology

"$SURF SRF813 (anti-PVRIG/CD112R) at #AACR20 $GSK (cf $CGEN COM701)" (@JacobPlieth)

Oncology

".@GSK taps @SurfaceOncology #immunotherapy program for $85M upfront + $730M milestones Acquires anti-PVRIG #antibody #SRF813 targeting inhibitory protein expressed in #NKcells & #Tcells https://t.co/a8soB29b6q #immunooncology #CellTherapy @TenBridge" (@DDNewsOnline)

Oncology

Surface Oncology to Participate in the 3rd Annual Evercore ISI HealthCONx Conference (GlobeNewswire) - “Surface Oncology…announced that Jeff Goater, chief executive officer, and Robert Ross, M.D., chief medical officer, will participate in the upcoming 3rd Annual Evercore ISI Global HealthCONx Conference on December 2, 2020 at 12:10 p.m. ET. The discussion will focus on Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting PVRIG, also known as CD112R) and SRF114 (targeting CCR8).”

Clinical • Preclinical • Oncology

Surface Oncology Reports Financial Results and Corporate Highlights for Third Quarter 2020 (GlobeNewswire) - “Selected Anticipated Near-term Corporate Milestones: Preclinical data presentations anticipated at Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting, November 11–14 2020. Initial clinical updates for both SRF617 and SRF388 anticipated by the end of 2020. Additional data presentations anticipated at scientific and medical conferences during the first half of 2021, including detailed clinical data presentations for SRF617 and SRF388. Investigational new drug (IND) filing for SRF813 anticipated in mid-2021.”

IND • P1 data • Preclinical • Oncology

Surface Oncology to Present at the Baird Global Healthcare Conference (GlobeNewswire) - "Surface Oncology...announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will present at the upcoming Robert W. Baird Global Healthcare Conference, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG). The presentation will be in the format of a fireside chat and take place virtually on Thursday September 10, 2020 at 1:25 pm EDT."

Clinical • Preclinical • Oncology

Surface Oncology to Participate in the H.C. Wainwright Global Healthcare Conference (GlobeNewswire) - "Surface Oncology...announced that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming H.C. Wainwright Global Healthcare Conference held on September 14/15, 2020, discussing Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG)."

Clinical • Preclinical • Oncology

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2020 (GlobeNewswire) - "Preclinical data presentations anticipated at Society for Immunotherapy of Cancer (SITC) in November 2020. Initial clinical updates for both SRF617 and SRF388 anticipated by the end of 2020. IND filing for SRF813 mid 2021."

IND • Preclinical • Oncology

[VIRTUAL] SRF813, a fully human monoclonal antibody targeting the inhibitory receptor CD112R, enhances immune cell activation and demonstrates preclinical in vivo anti-tumor activity (AACR-II 2020) - "Moreover, the combination of anti-CD112R with PD-1 blockade led to greater inhibition of tumor growth than either treatment alone. Collectively, these preclinical data demonstrated that CD112R is a negative regulator of immune responses and that CD112R blockade can potentiate anti-tumor responses in cancers that express CD112."

IO Biomarker • Preclinical • Oncology • CD8 • ICAM1

Surface Oncology to present preclinical data for multiple product programs at the American Association for Cancer Research Annual Meeting (GlobeNewswire) - "Surface Oncology...announced five scientific posters sharing updated preclinical data at the American Association for Cancer Research (AACR) 2020 Annual Meeting, to be held virtually on June 22-24. The posters include preclinical data from Surface Oncology’s two lead clinical-stage antibody therapies: SRF617 (targeting CD39) and SRF388 (targeting IL-27). Three additional posters containing preclinical data from SRF813 (targeting CD112R) and SRF231 (targeting CD47) will also be presented."

Preclinical • Hematological Malignancies • Oncology • Ovarian Cancer • Renal Cell Carcinoma

Surface Oncology fully utilizes its $30M at-the-market facility (GlobeNewswire) - "These funds strengthen Surface Oncology’s balance sheet and will be used to advance its pipeline, including the clinical development of SRF617 (targeting CD39) and SRF388 (targeting IL-27), and the advancement of SRF813 (targeting CD112R, also known as PVRIG), as well as for working capital and other general corporate purposes."

Financing • Oncology